Average 2-5 g/day
Ukrain: 5-20 mg parenterally qD-q3d
Cancer: 50-300 mg IV qDay, with 100 mg IV qday most common
Available in Europe & Mexico & alternative/complementary health centers in the US
Oral: 1 mL TID
Intestinal spasms, dyspepsia, liver disease, prevention of gallstone formation
Ukrain (celandine+thiotepa): cancers
Approved by German Commission E for intestinal spasms
Ukrain has selective cytotoicity against neoplastic cells in vitro; also some positive results but in small & possibly poorly-designed clinical studies
Serious - Use Alternative
Significant - Monitor Closely
Rashes, itching, serious allergic reactions
Potential risk of hepatitis
Parts of the plant (esp roots) may be toxic
Pregnancy & Lactation
Pregnancy Category: avoid
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action